10-Q: Cue Biopharma Reports Q1 2025 Results, Highlights Boehringer Ingelheim Collaboration and License Agreement

Cue Biopharma announces its Q1 2025 financial results, emphasizing a new collaboration with Boehringer Ingelheim and ongoing efforts to secure additional funding amidst going concern uncertainties.

Summary

• Cue Biopharma, a clinical-stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2025.
• The company is developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells.
• Cue Biopharma has incurred recurring losses and negative cash flows from operations since its inception.
• As of March 31, 2025, the company had cash and cash equivalents of $13.1 million.
• In April 2025, Cue Biopharma received approximately $18.0 million in net proceeds from a public offering.
• Also in April 2025, the company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BI), receiving an upfront payment of approximately $12.0 million.
• The company is exploring additional capital through equity offerings, collaborations, and strategic alliances.
• There is substantial doubt about the company's ability to continue as a going concern within one year of the issuance date of these financial statements.
• Collaboration revenue for the three months ended March 31, 2025, was $421,000, compared to $1.7 million for the same period in 2024.
• Research and development expenses decreased by $1.7 million to $8.5 million for the three months ended March 31, 2025.
• The company expects to file an investigational new drug, or IND, application in the third quarter of 2026, with human proof-of-mechanism data anticipated in the first half of 2027, subject to sufficient funding.
• The company and Ono agreed to terminate the Ono Collaboration and Option Agreement effective as of March 6, 2025.
• The company regained its rights to the LG Chem Territory for the CUE-101 program which had been licensed to LG Chem, and LG Chem terminated all of its rights to the same program.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. The collaboration with Boehringer Ingelheim and the recent public offering are positive developments. However, the company's financial losses, going concern uncertainty, and decreased collaboration revenue weigh heavily on the overall sentiment.

Positives

• The company secured a collaboration and license agreement with Boehringer Ingelheim, providing an upfront payment of $12.0 million and potential milestone payments of up to $345.0 million.
• The company completed a public offering in April 2025, raising approximately $18.0 million in net proceeds.
• The company regained rights to the CUE-101 program in the LG Chem Territory.
• The company is preparing to file an IND application for CUE-401 in the third quarter of 2026.

Negatives

• The company has a history of recurring losses and negative cash flows from operations.
• There is substantial doubt about the company's ability to continue as a going concern.
• Collaboration revenue decreased significantly compared to the prior year.
• The company terminated the Ono Collaboration and Option Agreement.

Risks

• The company's recurring losses from operations raise substantial doubt regarding its ability to continue as a going concern.
• The company will need substantial additional financing to support its growth and ongoing operations.
• Volatility in capital markets and general economic conditions may be a significant obstacle to raising the required funds.
• Changes in and uncertainty surrounding U.S. trade policy could have a material adverse impact on the company's business.
• Failure to comply with the continued listing requirements of Nasdaq could result in delisting and negatively impact the share price.
• The company is dependent on the success of its drug product candidates, only two of which are currently being tested in clinical trials.

Future Outlook

Cue Biopharma believes its existing cash and cash equivalents, along with proceeds from the April 2025 offering and the upfront payment from Boehringer Ingelheim, will enable it to fund operations into the second quarter of 2026, but will need to raise substantial additional capital to fund its future operations and remain as a going concern.

Industry Context

Cue Biopharma is operating in the competitive biopharmaceutical industry, focusing on immuno-oncology and autoimmune diseases. The collaboration with Boehringer Ingelheim is a strategic move to advance its CUE-500 series, while prioritizing CUE-401 development. The company faces competition from other biotechnology and pharmaceutical companies developing similar therapies.

Comparison to Industry Standards

• Given the limited information, a detailed comparison to industry standards is challenging.
• However, the company's reliance on collaborations and equity offerings for funding is a common strategy for clinical-stage biopharmaceutical companies.
• Comparable companies in the immuno-oncology space include Adaptimmune, Iovance Biotherapeutics, and TCR2 Therapeutics, which also focus on T-cell therapies.
• These companies often have similar financial profiles, with high R&D expenses and reliance on external funding.
• The $345 million potential milestone payments from Boehringer Ingelheim are within the typical range for such collaborations in the biopharmaceutical industry.
• However, the company's going concern uncertainty is a significant concern and distinguishes it from more financially stable peers.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees face uncertainty due to the company's financial instability.
• Customers (potential patients) may experience delays in the development of new therapies.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.
• The collaboration with Boehringer Ingelheim could benefit stakeholders if it leads to successful drug development and commercialization.

Next Steps

• Continue the preclinical development of CUE-401 and the CUE-500 series (excluding CUE-501, which has been licensed to BI).
• Continue to assess maturing clinical data of our CUE-100 series, including CUE-101 and CUE-102, which we have deprioritized.
• Leverage our programs, including our autoimmune programs, to advance our other drug product candidates into preclinical and clinical development.
• Seek regulatory approvals for any drug product candidates for which we successfully complete clinical trials.
• Seek to discover and develop additional drug product candidates.
• Establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any drug product candidates for which we may obtain marketing approval and intend to commercialize on our own or jointly.
• Expand our manufacturing, quality, operational, financial and management systems, including personnel to support these functions.
• Maintain, expand and protect our intellectual property portfolio.
• Acquire or in-license other drug product candidates and technologies.
• Incur additional legal, accounting and other expenses in operating as a public company.

Key Dates

Keywords

Cue Biopharma, Boehringer Ingelheim, collaboration, financial results, biopharmaceutical, T cells, CUE-401, CUE-501, clinical trials, funding, milestone payments, revenue, losses, going concern